Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 234 full-time employees. The company went IPO on 2022-10-20. The company deploys its Prime Editing platform, a gene editing technology, to develop a new class of differentiated, one-time genetic therapies. The company is engaged in developing Prime Editors as a new class of therapeutics with transformative potential to expand the application of curative precision genetic medicines. The company has built a diversified portfolio of investigational therapeutic programs organized around core areas of focus, namely hematology and immunology, liver, lung, ocular and neuromuscular. The programs within its other areas of focus are on earlier stages of preclinical development and include Liver programs, such as Wilson's disease and glycogen storage disease 1b; Lung program, such as Cystic fibrosis; Ocular program, such as Retinitis pigmentosa caused by Rhodopsin mutations, and Neuromuscular programs, including Friedreich's ataxia and myotonic dystrophy type 1.